Journal Thoracic Oncology

Abstracts Journal of Thoracic Oncology • Volume 12 Issue S1 January 2017
nonmucinous lung adenocarcinoma, the 8th edition TNM proposal to use
invasive rather than total size for the pT descriptor gives better prognostic
discrimination by capturing a larger number of patients with favorable
prognosis (pT1a) and providing better stratification for pT2b.
as surgical specimen with histological type of adenocarcinoma and NSCLC
NOS (Not Otherwise Specified) were routinely analyzed independent of the
tumor stage and clinical characteristics (reflex testing) for these genetic
alterations. Since January 2010 the EGFR mutation detection was performed
with the EGFR Mutation Test Kit from ROCHE on a COBAS4800. Since August
2011 tumor tissue was analyzed for EML4-ALK with a two-step procedure.
First an immunohistochemical staining was done with the Ventana anti
ALK(D5F3), OptiView DAB IHC DetectionKit and OptiViewAmplifikationKit®
and further on positive cases were tested by PCR (AmoyDx®EML4-ALK
FusionGeneDetectionKit) or ALK FISH (dual colour breakapart FISH/Abbott
Vysis®). Since January 2014 the tumor tissue was analyzed for ROS1 with a
two-step procedure. First an immunohistochemical staining was done with
ROS1 D4D6, cell signaling® and further on positive cases were tested by PCR
(AmoyDx®ROS1 GeneFusionDetectionKit) or ROS1 FISH (ROS1-6q22.1 dual
colour breakapart probe ZytoVision®). BRAF testing was performed with the
cobas®4800BRAF V600Mutation Test from Roche since March 2016. Results:
An EGFR Mutation was found in 340 out of 2776 patients (12.2%). 253 patients
(9.1%) carried an activated mutation (Exon 19 Deletion, Exon 21 L858R). EML4-
ALK positive translocation was found in 100 out of 2212 patients (4.5%).
ROS1 positive translocation was found in 5 out of 1060 patients (0.5%). BRAF
mutation was found in 3 patients out of 40 (7.5%). Conclusion: Frequency of
these genetic alterations in Austrian patients with NSCLC was quite similar to
other Caucasian peers. Therefore reflex testing is recommended independent
of any clinical characterization.
Keywords: Non-small-cell lung cancer, Target therapy
POSTER SESSION 1 - P1.04: PULMONOLOGY –
MONDAY, DECEMBER 5, 2016
P1.04-002 POSITIVE AIRWAY PRESSURE-ENHANCED CT TO
IMPROVE VIRTUAL BRONCHOSCOPIC NAVIGATION
Marta Diez-Ferrer 1 , Debora Gil 2 , Elena Carreño 3 , Susana Padrones 1 , Samantha
Aso 1 , Vanesa Vicens 1 , Noelia Cubero 1 , Rosa Lopez-Lisbona 1 , Carles Sanchez 2 ,
Agnes Borras 2 , Jordi Dorca 1 , Antoni Rosell 1
1 Respiratory Medicine, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat/
Spain, 2 Computer Vision Center, Bellaterra/Spain, 3 Radiology, Hospital Universitari
de Bellvitge, L’Hospitalet de Llobregat/Spain
Keywords: TNM staging, T factor, Invasive adenocarcinoma, Tumor size
POSTER SESSION 1 - P1.04: PULMONOLOGY –
MONDAY, DECEMBER 5, 2016
Background: A main weakness of virtual bronchoscopic navigation (VBN)
is unsuccessful segmentation of distal branches approaching peripheral
pulmonary nodules (PPN). CT scan acquisition protocol is pivotal for
segmentation covering the utmost periphery. We hypothesize that
application of continuous positive airway pressure (CPAP) during CT
acquisition could improve visualization and segmentation of peripheral
bronchi. The purpose of the present pilot study is to compare quality of
segmentations under 4 CT acquisition modes: inspiration (INSP), expiration
(EXP) and both with CPAP (INSP-CPAP and EXP-CPAP). Methods: In 10
patients 320-detector row CT scans with slice thickness of 0.5 mm were
performed in the 4 modes. In first 5 patients a pressure ranging 6-10 cmH 2
O
was applied for 3 min immediately before CT acquisition (CPAP6-10).
In following 5 a pressure of 10 cmH 2
O was applied, followed by 3 min of
expiratory maneuvers and non-CPAP acquisitions (CPAP10). Segmentations
were obtained and measurements manually calculated with a VBN
system (LungPoint, Broncus Technologies, Inc., Mountain View, CA, USA).
Comparisons for the inspiratory and expiratory models were made upon main
airways area (proximal trachea, distal trachea and main bronchi) and distance
of the path to the nodule (DIST-PN). Also, 2 random bronchi per lobe were
selected and the number of bifurcations (BIF) and distance (DIST) from carina
to the very end of the selected bronchi were manually counted and median
calculated. Statistical analyses with R-3.2.3. Results: See table 1.
P1.04-001 EGFR, EML4-ALK, ROS 1 AND BRAF TESTING IN AUSTRIAN
PATIENTS WITH NSCLC: A MULTICENTRE STUDY
Sophia Holzer 1 , Maximilian Hochmair 1 , Ulrike Setinek 2 , Dagmar Krenbek 2 ,
Hannah Fabikan 1 , Rosemarie Rumbold 1 , Andrea Mohn-Staudner 1 , Klaus
Kirchbacher 3 , Madeleine Arns 1 , Tatjana Bundalo 4 , Kurt Patocka 5 , Otto
Burghuber 1
1 Otto Wagner Hospital, Department of Respiratory and Critical Care Medicine,
Vienna/Austria, 2 Pathological-Bacteriological Institute, Otto Wagner Hospital,
Vienna/Austria, 3 Wilhelminenspital, Department Medicine Ii, Vienna/Austria,
4 Landeskrankenhaus Hochegg, Department of Pneumology, Grimmenstein/Austria,
5 Krankenhaus Hietzing, Department of Pneumology, Vienna/Austria
Background: Targeted therapy is becoming increasingly important and
has improved the overall survival for patients with NSCLC. EGFR and BRAF
mutations, EML4-ALK and ROS1 translocations are current allocatable targets.
The incidence of these druggable targets in Austria is unknown. Methods:
Tumor tissue from bronchoscopy, CT- and ultrasound guided biopsies as well
Copyright © 2016 by the International Association for the Study of Lung Cancer
S307